423 related articles for article (PubMed ID: 26881508)
21. A comparison of six fractions per week chemoradiation versus five fractions per week of conventional chemoradiation in carcinoma cervix: A prospective controlled study.
Kumar D; Pradhan S; Choudhary S; Aggarwal LM; Das A; Sarangdhar S; Kaser P; Dewangan S
J Cancer Res Ther; 2019; 15(6):1296-1303. PubMed ID: 31898663
[TBL] [Abstract][Full Text] [Related]
22. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
[TBL] [Abstract][Full Text] [Related]
23. Concurrent chemo-irradiation using accelerated concomitant boost radiation therapy in loco-regionally advanced head and neck squamous cell carcinomas.
Vivek RS; Baludavid M; Mohanram R; ; ; ; ; ;
J Cancer Res Ther; 2006; 2(3):90-6. PubMed ID: 17998685
[TBL] [Abstract][Full Text] [Related]
24. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.
Fu KK; Pajak TF; Trotti A; Jones CU; Spencer SA; Phillips TL; Garden AS; Ridge JA; Cooper JS; Ang KK
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):7-16. PubMed ID: 10924966
[TBL] [Abstract][Full Text] [Related]
25. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial.
Horiot JC; Bontemps P; van den Bogaert W; Le Fur R; van den Weijngaert D; Bolla M; Bernier J; Lusinchi A; Stuschke M; Lopez-Torrecilla J; Begg AC; Pierart M; Collette L
Radiother Oncol; 1997 Aug; 44(2):111-21. PubMed ID: 9288839
[TBL] [Abstract][Full Text] [Related]
26. Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial.
Magrini SM; Buglione M; Corvò R; Pirtoli L; Paiar F; Ponticelli P; Petrucci A; Bacigalupo A; Crociani M; Lastrucci L; Vecchio S; Bonomo P; Pasinetti N; Triggiani L; Cavagnini R; Costa L; Tonoli S; Maddalo M; Grisanti S
J Clin Oncol; 2016 Feb; 34(5):427-35. PubMed ID: 26644536
[TBL] [Abstract][Full Text] [Related]
27. Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
Noronha V; Joshi A; Patil VM; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; D'Cruz AK; Banavali S; Pai PS; Chaturvedi P; Chaukar D; Pande N; Chandrasekharan A; Talreja V; Vallathol DH; Mathrudev V; Manjrekar A; Maske K; Bhelekar AS; Nawale K; Kannan S; Gota V; Bhattacharjee A; Kane S; Juvekar SL; Prabhash K
J Clin Oncol; 2018 Apr; 36(11):1064-1072. PubMed ID: 29220295
[TBL] [Abstract][Full Text] [Related]
28. Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial.
Budach V; Becker ET; Boehmer D; Badakhshi H; Jahn U; Wernecke KD; Stromberger C
Strahlenther Onkol; 2014 Mar; 190(3):250-5. PubMed ID: 24322993
[TBL] [Abstract][Full Text] [Related]
29. A comparative study of concomitant boost radiation versus concomitant boost with concurrent chemoradiation versus standard fractionation chemoradiation in locally advanced head-and-neck cancer.
Gupta P; Dhull AK; Kaushal V
J Cancer Res Ther; 2020; 16(3):478-484. PubMed ID: 32719254
[TBL] [Abstract][Full Text] [Related]
30. Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study.
Cvek J; Kubes J; Skacelikova E; Otahal B; Kominek P; Halamka M; Feltl D
Strahlenther Onkol; 2012 Aug; 188(8):666-70. PubMed ID: 22648405
[TBL] [Abstract][Full Text] [Related]
31. Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study.
Jegannathen A; Mais K; Sykes A; Lee L; Yap B; Birzgalis A; Homer J; Ryder WD; Slevin N
Clin Oncol (R Coll Radiol); 2011 Mar; 23(2):149-58. PubMed ID: 20951012
[TBL] [Abstract][Full Text] [Related]
32. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study.
Poulsen MG; Denham JW; Peters LJ; Lamb DS; Spry NA; Hindley A; Krawitz H; Hamilton C; Keller J; Tripcony L; Walker Q
Radiother Oncol; 2001 Aug; 60(2):113-22. PubMed ID: 11439206
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
[TBL] [Abstract][Full Text] [Related]
34. Different fractionation schedules of radiotherapy in locally advanced head and neck malignancy: A prospective randomized study to compare the results of treatment and toxicities of different protocols.
Majumder D; Choudhury K; Das P; Kundu S; Mitra D
South Asian J Cancer; 2013 Jan; 2(1):31-5. PubMed ID: 24455542
[TBL] [Abstract][Full Text] [Related]
35. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
[TBL] [Abstract][Full Text] [Related]
36. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
Iocca O; Farcomeni A; Di Rocco A; Di Maio P; Golusinski P; Pardiñas López S; Savo A; Pellini R; Spriano G
Oral Oncol; 2018 May; 80():40-51. PubMed ID: 29706187
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
[TBL] [Abstract][Full Text] [Related]
38. Functional organ preservation after chemoradiotherapy in elderly patients with loco-regionally advanced head and neck squamous cell carcinoma.
Boscolo-Rizzo P; Muzzi E; Trabalzini F; Gava A; Stellin M; Da Mosto MC
Eur Arch Otorhinolaryngol; 2011 Sep; 268(9):1349-55. PubMed ID: 21258812
[TBL] [Abstract][Full Text] [Related]
39. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
Mesía R; Henke M; Fortin A; Minn H; Yunes Ancona AC; Cmelak A; Markowitz AB; Hotte SJ; Singh S; Chan AT; Merlano MC; Skladowski K; Zhang A; Oliner KS; VanderWalde A; Giralt J
Lancet Oncol; 2015 Feb; 16(2):208-20. PubMed ID: 25596660
[TBL] [Abstract][Full Text] [Related]
40. Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
Franco P; Potenza I; Schena M; Riva G; Pecorari G; Garzino Demo P; Fasolis M; Moretto F; Garzaro M; Di Muzio J; Melano M; Airoldi M; Ragona R; Rampino M; Ricardi U
Anticancer Res; 2015 Nov; 35(11):6247-54. PubMed ID: 26504058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]